159results about How to "Increase excretion" patented technology

Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with novel vectors, a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special vectors are provided which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.

There is provided a 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

A Chinese medicine for preventing and treating cholecystitis, cholelithiasis and the inflammation of biliary tract, and improving the function of gallbladder and liver is prepared from 23 Chinese-medicinal materials including tackahoe, capejasmine fruit, white peony root, cyprus tuber, etc.

There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

The present invention relates to novel antagonists to a B₁-bradykinin (B₁-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B₁ receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B₁-BK receptors in these two models. B₁-BK antagonists abolished the vasocontraction induced by B₁-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B₁-antagonists are useful for treating any condition wherein B₁-receptor is expressed, particularly during inflammation, and more particularly wherein B₁-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B₁-receptor.

The invention discloses Al18F-NOTA-PEG6-TATE of a targeted somatostatin receptor and a preparation method and application of Al18F-NOTA-PEG6-TATE. The preparation method of the label includes the steps that a somatostatin derivative TATE and a difunctional chelating agent NOTA are connected through PEG to generate a radiolabelled precursor, then positron nuclide 18F labeling is carried out through a one-pot method, and the 18F labeled somatostatin derivative Al18F-NOTA-PEG6-TATE can be obtained. The method can be carried out in an acetate buffer solution system or an acetonitrile reaction system, and the method has the advantages of being easy and convenient to operate and high in labeling rate and product purity. The prepared positron label of the targeted somatostatin receptor can be applied to preparation of a PET/CT molecular probe or tumor therapy medicine, and provides a novel thought for synthesis of the clinical PET/CT molecular probe.

The present invention relates to a method for increasing in a baked product, after baking, the level of water-soluble arabinoxylan with an average degree of polymerization ranging from 5 to 50, preferably ranging from 5 to 35, more preferably ranging from 5 to 25, said method comprising the steps of:—Preparing a dough for a baked product with flour, a mixture of flours or a mixture of flour (s) with milling fractions having a total arabinoxylan content of at least 2.0%, preferably at least 2.5%, and—Adding to said dough an enzyme preparation comprising at least one thermophilic endoxylanase in an amount at least 2-fold higher, preferably at least 3 to 6 times higher or even 10 times higher than the dose conferring 90% of the maximal bread volume increase obtained by addition of such enzyme preparation to the recipe of said baked product. Advantageously with said method baked products can be obtained that have a level of arabinoxylan of the desired type of at least 1.7%, more preferably at least 1.75%, such as at least 1.8%, 1.9% or 2.0%. The present invention further relates to baked products obtainable by this method, and to an improver and a dough which may be used for the preparation of such products. Baked products according to the invention advantageously have improved health benefits.

The invention discloses a color-protecting and fresh-keeping method for fresh-cut potatoes. The method includes selecting fresh or stored potatoes as the raw material, washing cleanly, peeling, cutting into chips with thicknesses of 0.5-1.0mm, adding a composite color-protecting fresh-keeping solution having the same mass with the potato chips, and soaking for 10-30min at 20 DEG C-30 DEG C; then fishing out the potato chips from the composite color-protecting fresh-keeping solution, washing cleanly with water, soaking in water at 10-150w ultrasonic power and 10-50kHz ultrasonic frequency for 10-30min of ultrasonic time; fishing out the potato chips and draining off, processing for 10-30min under the condition of subzero 0.01MPa-subzero 0.09MPa of vacuum degree; and finally taking the potato chips out of the vacuum environment and soaking immediately into an arbutin solution with the concentration of 0.05-0.3mmol/L, soaking for 5-15min, taking the soaked potato chips out and draining for 1-3min, performing decompression packaging immediately, and storing at an environment of subzero 4 DEG C to zero DEGC. The method adopts ultrasonic and vacuum cooperative processing as well as the Chinese herb extract arbutin as the color-protecting fresh-keeping agent to inhibit enzyme and microbial activities, is better in effect compared with the prior art, and ensures that various potato processed products are prevented from brown stain in a cold storage process for more than 10 days.

A compound represented by the formula:

wherein Ar represents a group represented by the formula:

(wherein Y represents methylene or an oxygen atom, R¹ represents aminosulfonyl, C_1-6 alkylaminosulfonyl, C_1-6 alkylcarbonylamino or C_1-6 alkylsulfonylamino, R² represents a hydrogen atom or C_1-6 alkyl, R³ represents C_1-6 alkyl, and R⁴ represents a hydrogen atom or C_1-6 alkyl); X represents a carbonyl group, or a methylene group which may be substituted with a hydroxy group; and L represents an optionally substituted C_4-5 alkylene group, or a salt thereof is provided.

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.

The invention discloses a traditional Chinese medicine formula with effects of removing freckles and whitening and a preparation method thereof and belongs to the technical field of human health careproducts. The traditional Chinese medicine formula contains the following raw materials: 4-18 parts of ganoderma lucidum, 9-36 parts of tricholoma matsutake, 3-12 parts of ginseng, 1-4 parts of bearberry leaf extract, 3-12 parts of rhizoma polygonati, 3-12 parts of bighead atractylodes rhizome, 1-6 parts of bletilla striata, 3-12 parts of white paeony root, 3-12 parts of ampelopsis japonica, 3-12parts of silkworm larva, 4-12 parts of poria cocos, 1-6 parts of angelica sinensis, 3-9 parts of paeonia lactiflora, 3-12 parts of astragalus, 1-5 parts of almond, 2-10 parts of semen coicis, 1-5 parts of fructus kochiae, 1-5 parts of cortex dictamni, 1-5 parts of liquorice and 2-6 parts of mint. The whitening and freckle removing skin care product provided by the invention is mild and non-irritating, can be applicable to population with sensitive skin, is simple and convenient to use, natural and zero in side effect and has excellent application prospects.

The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.

Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D₅W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.